SCHEMBL22130646

SCHEMBL22130646

CC(=O)NCC1=Cc2c(c(-c3ccccc3)cn2S(=O)(=O)c2ccccc2)C(=O)C1=O

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ELAVL1 Q15717 7/20 0.56
▸ HTR6 P50406 6/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ LMNA P02545 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ MTNR1A P48039 1/20 0.36
▸ MTNR1B P49286 1/20 0.36
▸ PDCD1 Q15116 1/20 0.35
▸ CD274 Q9NZQ7 1/20 0.35
▸ PLK1 P53350 1/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22130647 0.89 ELAVL1 (0.54) ELAVL1MTNR1AMTNR1BPDCD1CD274
SCHEMBL22130680 0.87 ELAVL1 (0.47) ELAVL1HTR6SMN1; SMN2CA12CA1
SCHEMBL22130728 0.85 ELAVL1 (0.43) ELAVL1HTR6CD274
SCHEMBL22130645 0.85 ELAVL1 (0.62) ELAVL1HTR6L3MBTL1CA12CA1
SCHEMBL22130717 0.83 ELAVL1 (0.55) ELAVL1HTR6L3MBTL1LMNASMN1; SMN2
SCHEMBL22130702 0.82 ELAVL1 (0.56) ELAVL1HTR6L3MBTL1LMNASMN1; SMN2
SCHEMBL22130644 0.81 ELAVL1 (0.61) ELAVL1HTR6L3MBTL1CA12CA1
SCHEMBL22130676 0.78 KDM4E (0.40) ELAVL1LMNAMEN1KMT2A
SCHEMBL22130663 0.77 ELAVL1 (0.62) ELAVL1HTR6L3MBTL1LMNASMN1; SMN2
SCHEMBL22130705 0.77 ELAVL1 (0.65) ELAVL1HTR6L3MBTL1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy UNIVERSITA' DEGLI STUDI DI TRENTO (IT) 2020-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy AZI2, TPMT, TYMS ELAVL1 2765/4885HTR6 1922/4885L3MBTL1 4885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback